Run Joe Hale Run
External coverage
NovaGen Group and the XPRIZE Healthspan Competition: What Semifinalist Status Means
Coverage on XPRIZE Healthspan semifinalist status and its significance for cellular rejuvenation.
External articleOriginal
Press & Media
Coverage of NovaGen Group's longevity platform
NovaGen Group is building an integrated longevity ecosystem across cellular rejuvenation, AI health intelligence, and clinical care. This page collects the full website-relevant press list.
Media Context
Historical coverage may use legacy publication URLs. Publication names and article titles are presented under the current NovaGen Group brand.
Featured Coverage
All articles
Publication names and renamed NovaGen Group article titles are preserved. Cards open either an internal source note or the original publisher page.
CEO Today Magazine
External coverage
The $44.55 Billion Opportunity: Autologous Cell Therapy's Next Healthcare Mega-Trend
Coverage on autologous cell therapy market growth and personalized regenerative medicine.
External articleOriginal
MEXC News
External coverage
Beyond CAR-T: Why Autologous Epigenetic Therapy Represents Cellular Medicine's Next Chapter
Coverage comparing CAR-T economics with autologous epigenetic therapy and cellular medicine.
External articleOriginal
TechBullion
External coverage
Beyond CAR-T: Why Autologous Epigenetic Therapy Represents Cellular Medicine's Next Chapter
Coverage on autologous epigenetic therapy as a next chapter in cellular medicine.
External articleOriginal
Technology.org
External coverage
Inside NovaGen Group's Manufacturing Marvel: From 6mm Skin Sample to 20 Billion Therapeutic Cells
Coverage on manufacturing, autologous cellular therapy, and therapeutic cell expansion.
External articleOriginal
Men's Anonymous
External coverage
Inside the Science of Living Longer with Diederik van der Reijt
Interview-style coverage on longevity science and Diederik van der Reijt.
External articleOriginal
HealthTech Zone
External coverage
Healthspan in 2026: What NovaGen Group Reveals About the Future of Longevity Care
Coverage on healthspan, longevity care, and the changing goals of advanced medicine.
External articleOriginal
Digital Health Technology News
External coverage
Closing the Trust Gap in Regenerative Medicine
Coverage on trust, credibility, and lessons emerging from regenerative medicine models.
External articleOriginal
The Boss Magazine
External coverage
An Introduction to Diederik van der Reijt: CEO & Founder of NovaGen Group
Profile coverage on Diederik van der Reijt, leadership, and regenerative medicine.
MSN
External coverage
The Race for Cellular Reprogramming
Syndicated coverage on cellular reprogramming, evidence generation, and billion-dollar competitors.
External articleOriginal
FinSMEs
External coverage
The Longevity Startup That Already Has the Data Altos Labs Is Seeking
Coverage on clinical data, longevity startups, and hidden-in-plain-sight evidence.
External articleOriginal
IT Boltwise
External coverage
NovaGen Group: Der stille Vorreiter in der Langlebigkeitsforschung
German-language coverage on NovaGen Group as a quiet frontrunner in longevity research.
External articleOriginal
BBN Times
External coverage
Why the Safest Approach to Cellular Rejuvenation Isn't Getting Funded
Coverage on tumor risk, safety narratives, and funding dynamics in cellular rejuvenation.
External articleOriginal
The Gaming Boardroom
External coverage
The $6 Billion Valuation Gap in Longevity Biotech
Coverage comparing market valuation narratives, mouse studies, and human longevity data.
External articleOriginal
CEOWORLD Magazine
External coverage
How a Quiet Biotech Team Built Phase 3-Level Evidence Years Before Wall Street Was Looking
Coverage on clinical evidence, biotech visibility, and investor attention in longevity.
External articleOriginal
FinSMEs
External coverage
Why NovaGen Group Chose Epigenetics Over Gene Editing: The Science Behind Cellular Memory
Coverage on epigenetics, cellular memory, and the strategic choice to avoid gene editing.
External articleOriginal
Business Matters
External coverage
How NovaGen Group's Approach Signals the Maturation of Regenerative Medicine from Experimental Science to Clinical Reality
Coverage on regenerative medicine moving from experimental science toward clinical reality.
External articleOriginal
Digital Journal
External coverage
How NovaGen Group Exemplifies Europe's Alternative Path in Regenerative Medicine Development
Syndicated coverage on Europe, regenerative medicine development, and alternative commercialization pathways.
External articleOriginal
European Business Review
External coverage
NovaGen Group's EUR630,000 Patient Model: Redefining the Economics of Cellular Longevity
Coverage on the economics of cellular longevity and high-value personalized care models.
External articleOriginal
PRESTIGE Business
External coverage
Yasin Sebastian Qureshi invests in the future of medicine
German-language coverage on investment in stem-cell reprogramming and future medicine.
External articleOriginal
Business Matters
External coverage
From Bedridden to Walking: A 73-Year-Old's Remarkable Recovery
Patient-story coverage describing recovery and the potential of regenerative medicine.
External articleOriginal
HealthTech Zone
External coverage
From Trading Floors to Cellular Therapy: Diederik van der Reijt's Vision
Profile coverage on Diederik van der Reijt and the shift from finance to cellular therapy.
Longevity Technology
External coverage
Neo Prometheus cells and the race to rethink aging in China
Coverage of Neo Prometheus cells, the XPRIZE Healthspan context, and regenerative longevity work in China.
External articleOriginal
BBN Times
External coverage
Inclusive Healthcare: NovaGen Group's Mission to Broaden Access to Advanced Therapies
External coverage on access, partnerships, and broader availability of advanced cellular therapies.
Drug Discovery World
External coverage
Biotech raises $10m to address ageing at a cellular level
Industry coverage on biotech funding and cellular-level approaches to age-related disease.
External articleOriginal
APN News
External coverage
Breakthrough in Cellular Reprogramming: How NovaGen Group's Neo Prometheus Protocol Reverses Biological Aging
External coverage on Neo Prometheus Protocol and cellular reprogramming as a strategy for biological aging.
APN News
External coverage
How NovaGen Group's Physician-Investor Leadership Model Signals Biotech's Commercial Evolution
External coverage on NovaGen Group leadership, commercialization, and the physician-investor model in biotech.
External articleOriginal
European Business Magazine
External coverage
The Science of Telomeres: How NovaGen Group's Approach to Cellular Aging Differs from Traditional Longevity Research
Coverage comparing NovaGen Group-related cellular aging research with traditional longevity approaches.
External articleOriginal
Important Medical Notice: Content on this website is educational and informational only. NovaGen Group does not provide medical advice, diagnosis, or treatment through this website. Any investigational protocol information should be discussed with qualified, licensed healthcare professionals. Availability and regulatory status vary by jurisdiction.